What it sells
Turns scientific and regulatory knowledge into auditable workflows.
Business model breakdown
Buyer: who owns the budget?
UnverifiedRegulatory affairs, medical writing, clinical, safety and market-access teams at pharma, medtech, cosmetics and nutrition firms.
Trigger: what makes them buy now?
Fragmented evidence slowing regulated deliverables, manual error-prone workflows, and need for audit-ready AI traceability.
Workflow: what inputs become what output?
Governed AI workflows for document co-authoring, regulatory monitoring, safety signal triage, literature review and batch record QC, each with an evidence trail.
Economics: what it saves and how it charges
Claims 2-50x faster task completion; commercial model not shown.
Distribution: how it reaches customers
Direct sales ("Talk to an expert" CTAs).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-09-22 | Series A | €30M | — | biolevate.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.